Mutations in isocitrate dehydrogenase (IDH) play an increasing role in clinical assessment of human gliomas and determination of treatment. The performance of Chemical Shift Imaging (CSI) to detect 2-hydroxyglutarate (2HG) in mutant-IDH gliomas was assessed in the routine clinical environment. Specificity of 80% and sensitivity of 63% was achieved in a cohort of 15 patients scanned with the technique at 3T. Greater sensitivity, through longer acqusition or more sensitive equipment could result in reliable non-invasive detection of this putative biomarker present in a majority of Grade II/III gliomas.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords